|
Report No. : |
347818 |
|
Report Date : |
29.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
NIPPON FUNMATSU YAKUHIN CO LTD (YAKUHIN MEANS PHARMACEUTICAL) |
|
|
|
|
Registered Office : |
2-5-11 Doshomachi Chuoku Osaka 541-0045 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.03.2015 |
|
|
|
|
Date of Incorporation : |
September 1947 |
|
|
|
|
Com. Reg. No.: |
1200-01-093390 (Osaka-Chuoku) |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Manufactures intermediates &
ingredients for herbal medicines, health foods and cosmetics (--100%) |
|
|
|
|
No. of Employee : |
97 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
NIPPON FUNMATSU YAKUHIN CO LTD (YAKUHIN means
PHARMACEUTICAL)
REGD NAME: Nippon
Funmatsu Yakuhin KK
MAIN OFFICE: 2-5-11
Doshomachi Chuoku Osaka 541-0045 JAPAN
Tel: 06-6201-3801 Fax: 06-6222-4031
URL: http://www.nfy.co.jp
E-Mail address: nfo@nfy.co.jp
Mfg of herbal
medicines ingredients & intermediates, health foods, cosmetic materials
Tokyo
Osaka (2), Mie (1)
SHOICHI KUWANO,
PRES Kengo Ikeda, dir
Yasuo Takada, dir Akira Aota, dir
Yen Amount: In million Yen, unless otherwise stated
FINANCES FAIR A/SALES Yen 7,312 M
PAYMENTSNO COMPLAINTS CAPITAL Yen 60 M
TREND STEADY WORTH Yen 20,449 M
STARTED 1947 EMPLOYES 97
MFR OF CRUDE DRUGS
& CHINESE HERBAL MEDICINES.
FINANCIAL
SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS
ENGAGEMENTS.
The subject company was established by Teruichi Kuwano in order to make
most of his experience in the subject line of business. Shoichi is the founder’s son, who took the
pres office in Mar 1996. This firm is
wholly owned and operated by the Kuwano family, specializing in mfg
intermediates, ingredients & materials for herbal medicines, health foods
(herb-based) and cosmetics. 80% of the
materials & ingredients for mfg are directly imported from India, China,
Taiwan, Korea, Europe, other. Also
imported through general trading houses.
Domestic clients are major pharmaceutical mfrs, food mfrs, other,
nationwide. Medicines are produced at
three factories.
Financials are only partially disclosed.
The sales volume for Mar/2015 fiscal term
amounted to Yen 7,312 million, a 2% up from Yen 7,154 million in the previous
term. The net profit was posted at Yen
470 million, compared with Yen 450 million a year ago.
For the current term ending Mar 2016 the net profit is projected at Yen 485
million, on a 3% rise in turnover, to Yen 7,530 million. Demand for health foods and natural cosmetics
will expand.
The financial situation is considered FAIR and good for ORDINARY
business engagements.
Date Registered: Sept 1947
Regd No.;
1200-01-093390 (Osaka-Chuoku)
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 480,000 shares
Issued: 120,000 shares
Sum: Yen 60 million
Major shareholders (%): Company’s Treasury
Stock (45), Atlas Corp (30), Shoichi Kuwano (20) (% are all about)
No. of shareholders: 4
Nothing
detrimental is known as to the commercial morality of executives.
Activities: Manufactures
intermediates & ingredients for herbal medicines, health foods and cosmetics
(--100%)
(Items
manufactured):
For
pharmaceuticals: dried extracts, extracts, fluid extracts, disinfect powder, tincture,
etc;
For
Health Foods: extract powder, fluid extracts, other.
Manufacturing materials are imported from
China, India, Korea, Taiwan, Europe, other.
Clients: [Pharmaceutical
mfrs] House Food Inc, Takeda Pharmaceutical, Taisho Pharmaceutical, Chugai
Pharmaceutical, Mitsubishi Tanabe Pharma, Tanabe Chemical Corp, SSP Co,
Astellas Pharma, Kowa Co, Kurace Seiyaku, Daiichi Sangyo Healthcare, other.
No. of accounts:
500
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs,
wholesalers] Imports from China, Taiwan, India, Korea, Europe, other (--80%).
Domestically supplied from Economic
Federations of Hyogo-Pref, Nagano-Pref and Kochi-Pref, Zen-Noh, Itochu Corp,
other.
Payment record: No Complaints
Location: Business area in Osaka.
Office premises at the caption address are owned and maintained
satisfactorily.
Bank References:
Mizuho Bank
(Minami-Semba)
MUFG (Kawaramachi)
Relations:
Satisfactory
(In Million Yen)
|
Terms Ending: |
|
31/03/2016 |
31/03/2015 |
31/03/2014 |
31/03/2013 |
|
Annual
Sales |
|
7,530 |
7,312 |
7,154 |
6,772 |
|
Recur.
Profit |
|
.. |
.. |
.. |
.. |
|
Net
Profit |
|
485 |
470 |
450 |
400 |
|
Total
Assets |
|
|
N/A |
N/A |
N/A |
|
Net
Worth |
|
|
20,449 |
20,120 |
19,805 |
|
Capital,
Paid-Up |
|
|
60 |
60 |
60 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
|
(%) |
(%) |
(%) |
(%) |
|
S.Growth Rate |
|
2.98 |
2.21 |
5.64 |
7.46 |
|
Current Ratio |
|
|
.. |
.. |
.. |
|
N.Worth Ratio |
|
|
.. |
.. |
.. |
|
N.Profit/Sales |
|
6.44 |
6.43 |
6.29 |
5.91 |
Notes: Financials
are only partially disclosed.
Forecast (or
estimated) figures for the 31/03/2016 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.04 |
|
|
1 |
Rs.99.58 |
|
Euro |
1 |
Rs.71.75 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAS |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.